GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Debt-to-Revenue

Cybin (CYBN) Debt-to-Revenue : N/A (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cybin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.24 Mil. Cybin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.03 Mil. Cybin's annualized Revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

Cybin Debt-to-Revenue Historical Data

The historical data trend for Cybin's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Debt-to-Revenue Chart

Cybin Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Debt-to-Revenue
N/A - N/A N/A

Cybin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Cybin's Debt-to-Revenue

For the Biotechnology subindustry, Cybin's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cybin's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cybin's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cybin's Debt-to-Revenue falls into.


Cybin Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cybin's Debt-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / N/A
=N/A

Cybin's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.242 + 0.031) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Cybin Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cybin's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cybin (CYBN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (AMEX:CYBN) » Definitions » Debt-to-Revenue
Comparable Companies
TSX:FRX TSX:SVA TSX:ONC NEOE:MMED TSX:EPRX XCNQ:DTC TSXV:NGEN TSX:BCT XCNQ:MSET TSXV:ARCH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
R7E1:Germany R7E1:Germany CYBN:Canada
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Website
https://www.cybin.com
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.